Pacer Advisors Inc. Purchases 403,028 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Pacer Advisors Inc. lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 29.9% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,752,882 shares of the specialty pharmaceutical company’s stock after buying an additional 403,028 shares during the period. Pacer Advisors Inc.’s holdings in Supernus Pharmaceuticals were worth $54,655,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Supernus Pharmaceuticals by 97.1% in the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 398 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in Supernus Pharmaceuticals during the 1st quarter worth approximately $43,000. Meeder Asset Management Inc. bought a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $47,000. Innealta Capital LLC acquired a new position in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 352 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the transaction, the senior vice president now owns 8,200 shares in the company, valued at $303,236. The trade was a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 in the last ninety days. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Stock Down 0.8 %

SUPN stock opened at $35.82 on Friday. The company has a market cap of $1.98 billion, a price-to-earnings ratio of 33.48 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37. The business has a 50 day moving average price of $33.62 and a two-hundred day moving average price of $31.06.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The company’s quarterly revenue was up 14.2% compared to the same quarter last year. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.